Year: 2018
Type: article
Abstract: Zika virus (ZIKV) is a flavivirus that can cause congenital disease and requires development of an effective long-term preventative strategy. A replicative ZIKV vaccine with properties similar to the yellow fever 17D (YF17D) live-attenuated vaccine (LAV) would be advantageous, as a single dose of YF17D produces lifelong immunity. However, a replicative ZIKV vaccine must also be safe from causing persistent organ infections. Here we report an approach to ZIKV LAV development. We identify a ZIKV variant that produces small plaques due to interferon (IFN)-restricted viral propagation and displays attenuated infection of endothelial cells. We show that these properties collectively reduce the risk of organ infections and vertical transmission in a mouse model but remain sufficiently immunogenic to prevent wild-type ZIKV infection. Our findings suggest a strategy for the development of a safe but efficacious ZIKV LAV.
Source: Nature Communications
Authors: Swee Sen Kwek, Satoru Watanabe, Kuan Rong Chan, Eugenia Z. Ong, Hwee Cheng Tan, Wy Ching Ng, Mien T. X. Nguyen, Esther S. Gan, Summer L. Zhang, Kitti W. K. Chan, Jun Hao Tan, October M. Sessions, Menchie Manuel, Julien Pompon, Camillus Chua, Sharifah Hazirah, Karl Tryggvason, Subhash G. Vasudevan, Eng Eong Ooi
Institutions: National University of Singapore, Duke-NUS Medical School, Centre National de la Recherche Scientifique, Université de Montpellier, Maladies Infectieuses et Vecteurs: Écologie, Génétique, Évolution et Contrôle, Institut de Recherche pour le Développement, SingHealth, Karolinska Institutet, Singapore-MIT Alliance for Research and Technology
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $6,990
OpenAlex ID: W2792206614